Couple Dynamics: PPARγ and Its Ligand Partners  by Yu, Shanghai & Xu, H. Eric
Structure
Previewsinfluences on isotopic, organic, and
inorganic chemical signatures in rocks,
while powerful, are potentially subject
to the influence of diagenetic processes
and assumptions about ancient bio-
chemistries (Fischer et al., 2005). The
genome-based analyses, such as the
application of conserved protein folding
domains used by Kim et al. (2012), offer
an important new tool in constraining
this Proterozoic oceanscape. Yet, with
these technical advances also comes
a new challenge: the building of bridges
across the cultural and scientific divides
between biochemists and geochemists
in order to further explore the co-evolu-
tion of life and biogeochemistry
throughout Earth’s history.
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Ligand-regulated transcriptional activity is the most important property of nuclear receptors, including
PPARg. In this issue of Structure, Hughes et al. determined how the dynamic conformations of ligands
and the receptor contribute to the degree of ligand-dependent activation of PPARg, which provide further
insights into design of PPARg-based anti-diabetic drugs.PPARg, a key activator of adipogenesis,
is also the molecular target of the thiazoli-
dinedione (TZD) class of anti-diabetic
drugs such as rosiglitazone and pioglita-
zone. These TZD drugs are full agonists
of PPARg that are able to promote
adipocyte differentiation. Although TZDs
improve insulin sensitivity and glucose
metabolism, they have been associated
with severe side effects including fluid
retention, weight gain, and cardiovas-
cular diseases. The major challenge of
PPARg-based drug discovery is how
to retain the beneficial glucose-lowering
effects of PPARg ligands but avoid their -undesired side effects. The attempts to
overcome such challenges have been
blocked by the lack of basic under-
standing of how PPARg activation by
small molecule ligands is linked with
their anti-diabetic effects. A series of
recent papers, including the one by
Hughes et al. (2012) in this issue of
Structure, begin to shed light into
complex mechanisms that link PPARg
activity with insulin sensitivity and glucose
metabolism.
PPARg and two related receptors
PPARa and PPARd/b comprise a sub-
family of nuclear receptors, whose tran-scription activity is tightly controlled by
the conformation of an activation helix
(AF-2), which resides in the C terminus
of the ligand binding domain. PPARg is
known to have a ligand-independent
basal activity (Xu and Li, 2008). As shown
in Figure 1, in the absence of any ligand,
the AF-2 helix of PPARg is in equilibrium
between closed (active) and open (inac-
tive) conformations (Nolte et al., 1998).
The binding of activating ligands, such
as TZD or fatty acids, locks the AF-2 in
the active conformation through a tight
interaction between the AF-2 helix and
the bound ligand (Gampe et al., 2000;
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Figure 1. Dynamic Structures of PPARg in Apo and Various Ligand-
Bound States
Apo PPARg is shown with AF-2 helix, a hand-shaped ligand binding pocket
(PC) and the b sheet (b) near Ser-273, with the AF-2 helix in a balance between
open and closed conformations. The degree of Ser-273 phosphorylation is
shown with a red bar. Rosiglitazone (TZD) binding stabilizes the AF-2 and
the b sheet, reducing Ser-273 phosphorylation, while DA does not have an
effect on PPARg structure or Ser273-phosphorylation. MRL20 and MRL24
adopt multiple conformations in the PPARg pocket with different stabilization
of the AF-2 helix and the b sheet, thus affecting different levels of agonism and
Ser-273 phosphorylation.
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active conformation, the AF-2
helix forms a charge-clamp
pocket to interact with short
LXXLL motifs of coactivators
that are required for transcrip-
tional activation (Nolte et al.,
1998). In contrast, the bind-
ing of antagonists, as seen
in PPARa, destabilizes the
AF-2 helix from the active
conformation and opens up
the charge clamp pocket for
binding of larger LXXXIXXXL
motifs of corepressors (Xu
et al., 2002). For a long
time, it was widely believed
that transcriptional activity
of PPARg by TZDs was
responsible for TZD’s effects
on insulin sensitivity and
glucose regulation as the
in vitro affinity of PPARg
correlate with the potency of
their in vivo glucose lowering
activity (Willson et al., 1996).
This view is further supported
by recent evidence of adipo-
cyte specific-knockout of
nuclear corepressor NCoR,which increases PPARg transcriptional
activity and improves glucose metabo-
lism (Li et al., 2011).
However, the direct correlation
between PPARg transcriptional activity
of ligands and their anti-diabetic effects
has been challenged from the very begin-
ning. The first puzzle came from the
genetic knockout PPARg in mice, where
heterozygous mice, which have half
activity of wild-type, displayed more
robust insulin sensitivity and glucose
metabolism than wild-type mice (Barak
et al., 1999). Second, although specific
high affinity endogenous ligands have
not been identified (Xu and Li, 2008), fatty
acids are considered to be general
PPARg ligands that are present in suffi-
cient concentrations to activate PPARg
in vivo (Xu et al., 1999). It is not clear
why exogenous ligands would have
significant anti-diabetic effects. The final
puzzle lies in several PPARg ligands,
including MRL24, which have very poor
agonist activities but have very good
anti-diabetic effects (Choi et al., 2010).
These puzzles remain as the dark clouds
in the field of PPARg and diabetic
research.Recent works from the Spiegelman
and Griffin groups, which reveal the link
of inhibition of Cdk5 phosphorylation of
PPARg by rosiglitazone and MRL24
with their anti-diabetic effects, start to
provide answers to the third puzzle above
(Choi et al., 2010). Cdk5 phosphorylates
PPARg at Ser-273. Both rosiglitazone
and MRL24 inhibit this phosphorylation
(MRL24 does not directly stabilize the
AF-2 helix), and this inhibition is corre-
lated with its anti-diabetic outcome of
rosiglitazone in small clinical samples.
Furthermore, SR1824, a non-agonist
PPARg ligand that blocks Cdk5-mediated
phosphorylation, has similar anti-diabetic
effects as rosiglitazone, consistent with
the fact that Cdk5-mediated phosphory-
lation may play a major role in the devel-
opment of insulin resistance (Choi et al.,
2011). However, blocking the Cdk5-medi-
ated phosphorylation of PPARg may not
be the only path to develop PPARg-based
anti-diabetic drugs. PPARg has a large
ligand binding pocket comprising of
a small hydrophobic thumb pocket and
a larger palm-like pocket (Figure 1). Both
rosiglitazone and MRL24 dock into the
larger palm pocket and stabilize theStructure 20, January 11, 2012 ª2012 Eb sheet region of Ser-273,
thus blocking Cdk5 phos-
phorylation. However, dec-
anoic acid (DA), a 10-carbon
fatty acid derived from natural
middle chain-length triglycer-
ides, is a weak PPARg partial
agonist that binds to the
thumb pocket (Figure 1). DA
does not stabilize PPARg, in-
cluding the b sheet and AF-2
regions, thus it does not
inhibit Cdk5-mediated phos-
phorylation of PPARg. Inter-
estingly, DA was able to im-
prove metabolism of glucose
and lipids without induction
of adipogenesis and body
weight gain (Malapaka et al.,
2011), suggesting complex
mechanisms of PPARg-medi-
ated anti-diabetic effects
beyond inhibition of Cdk5
phosphorylation.
The paper by Hughes et al.
(2012) adds another layer of
complexity in PPARg-ligand
interactions. Through studies
of NMR and hydrogen/deute-
rium exchange, the authorsdiscovered that AF-2 moves between all
possible conformations on the interme-
diate NMR exchange time scale and the
degree of stabilization of the active AF-2
conformation by MRL24, MRL20, and ro-
siglitazone correlates with their agonist
activity (Figure 1). The most unexpected
discovery is the occurrence of themultiple
bound conformations of MRL20 and
MRL24 in the PPARg pocket, contradict-
ing the single conformation observed in
the earlier crystal structures (Bruning
et al., 2007). Correspondingly, the
receptor also adopts multiple conforma-
tions to accommodate the changes of
ligand conformations. This observation
challenges the prevalent view of one-
on-one ligand-receptor interactions with
respect to their bound conformations.
The multiple docking modes arisen from
promiscuous coupling between ligand
and the receptor has also added sig-
nificant difficulties in structure-based
design of PPARg-based anti-diabetic
drugs. The continued quest for better
PPARg-based anti-diabetic drugs will
have to be rooted in the field of PPARg
biology and pathology of diabetes, where
much remains to be learned.lsevier Ltd All rights reserved 3
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